News

Grenova Announces Katherine Marrs as New CEO to Drive Innovation and Growth

Grenova, an industry leader in sustainable laboratory solutions, has appointed Katherine Marrs as its new Chief Executive Officer (CEO). Marrs succeeds Lane Major, who has served as CEO since 2023 and will continue to support Grenova as a member of the Board of Directors.

Marrs has been instrumental in driving Grenova’s growth strategy as the company’s Chief Commercial Officer for the past 16 months. Her leadership has been pivotal in expanding Grenova’s presence in the European market and enhancing its commitment to sustainability within the Life Sciences industry.

“We are at an exciting juncture, and I am honored to lead Grenova as we drive forward,” said Marrs. “I look forward to building on our team’s accomplishments, enhancing our innovative product portfolio, advancing our automation and integration capabilities, and furthering our commitment to helping laboratories reduce their environmental footprint.”

Lane Major expressed his confidence in Marrs’ ability to lead Grenova into its next chapter. “Katherine has demonstrated remarkable vision and leadership during her time as Chief Commercial Officer. Her deep understanding of our business and commitment to innovation make her the perfect choice to lead Grenova.”

Ted Lundberg, Chairman of the Board of Directors for Grenova and Co-Founder of Peloton Equity, Grenova’s majority owner, said, “Katherine has shown remarkable skill in guiding Grenova’s commercial strategy and building a solid foundation for the company’s future. Her dedication, expertise, and strategic focus have proven invaluable, and we look forward to her continued success as CEO.”

As Grenova continues expanding its solutions, Marrs will leverage her expertise to enhance the company’s position in the market, foster partnerships that align with Grenova’s mission, and drive initiatives that further its dedication to environmental and economic responsibility.

 

Read more here.

Recent News

10/26/2026

ATCC Selected by ARPA-H to Support Next-Generation BioStabilization Technologies

ATCC has been selected by the Advanced Research Projects Agency for Health (ARPA-H) as an affiliate to provide independent verification and validation (IV&V) for its BioStabilization Systems (BoSS) program. Through this program, BoSS is taking the “200-degree leap,” from -196°C toward room temperature, to make life-saving cell therapies as easy to store and ship as …

10/26/2026

Adial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial Officer

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing treatments for serious inflammatory diseases, today announced that Celia Economides, the Company’s current Executive Vice President of Finance, is expected to be appointed Chief Financial Officer effective promptly after the Company’s reconvened 2026 Annual Meeting of Stockholders, if certain …

10/23/2026

PAK BioSolutions and iBET Advance Integrated Continuous AAV8 Purification

PAK BioSolutions today announced the publication of a peer-reviewed study on integrated, continuous purification of adeno-associated virus serotype 8 (AAV8) using the PAK PD™ Process Development Scale Continuous Purification System. Conducted in collaboration with iBET – Instituto de Biologia Experimental e Tecnológica, the study, “Streamlining AAV8 Purification with Cyclic Integrated Capture–Polishing Chromatography,” was published in …